Dechra Pharmaceuticals’ (DPH) “Hold” Rating Reaffirmed at Jefferies Group

Jefferies Group restated their hold rating on shares of Dechra Pharmaceuticals (LON:DPH) in a research report sent to investors on Wednesday, January 17th. The firm currently has a GBX 2,221 ($31.14) target price on the stock.

Dechra Pharmaceuticals (LON DPH) traded down GBX 8 ($0.11) during trading on Wednesday, hitting GBX 2,238 ($31.38). 592,625 shares of the stock were exchanged, compared to its average volume of 184,659. Dechra Pharmaceuticals has a one year low of GBX 1,530 ($21.45) and a one year high of GBX 2,458 ($34.46). The firm has a market cap of $2,070.00 and a P/E ratio of 7,992.86.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://stocknewstimes.com/2018/02/11/jefferies-group-reaffirms-hold-rating-for-dechra-pharmaceuticals-dph.html.

About Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Analyst Recommendations for Dechra Pharmaceuticals (LON:DPH)

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply